AIM ImmunoTech Inc. (AIM)
Oxford Ledge is still expanding full research coverage of AIM. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
AIM ImmunoTech develops immuno-pharma therapeutics, primarily focusing Ampligen on pancreatic cancer treatment and exploring applications in other cancers and viral diseases.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-25
- S-1 IPO / securities registration statement 2026-06-18
- 8-K Other material event; Financial statements and exhibits 2026-06-15
- 8-K Entry into material agreement; 3.02; Other material event; Financial statements and exhibits 2026-06-11
- 8-K Amendments to articles or bylaws; Financial statements and exhibits 2026-06-10
Source: SEC EDGAR.
Annual results
5 years of annual figures for AIM, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $88,000 | -$14.0M | -$8.62 |
| 2024 | $170,000 | -$17.3M | -$30.92 |
| 2023 | $202,000 | -$29.0M | -$0.60 |
| 2022 | $141,000 | -$19.4M | -$0.40 |
| 2021 | $135,000 | -$19.1M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for AIM. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AIM in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.